New Rhein Healthcare Investors
New Rhein Healthcare Investors is a venture capital firm that applies a private equity business model to life sciences investing. The firm focuses on assets with proven clinical safety and efficacy, applied in innovative ways such as new delivery forms or indications. New Rhein aims to develop products that offer significant health benefits to patients and economic value to payors. The firm takes significant stakes in a small number of companies, actively managing their value creation to limit science-based risk and concentrate on successful product development and commercialization.
New Rhein Healthcare Investors
Two Logan Square, Suite 1930, Philadelphia PA 19103
What We Do
New Rhein takes an active role in managing portfolio companies, contributing operational experience, relationship networks, and business acumen to build value.
The firm combines significant deal-making expertise with deep operating experience, allowing it to tailor the right plan for each opportunity and sustainably scale businesses.
New Rhein compiles syndicates of operationally focused investors who bring a wealth of experience and a broad network of relationships to support its portfolio companies.
Industry Focus
Investment Range
Investment Stage
Portfolio
Developing a prodrug of treprostinil delivered on a proprietary transdermal patch to treat pulmonary arterial hypertension (PAH).
#Pharmaceuticals
US-based sterile injectable manufacturer focused on ready-to-use pre-filled syringes and vials.
#Pharmaceuticals
Developing a minimally invasive implantable device for the treatment of benign prostatic hyperplasia (BPH).
#Medical Devices
Developing an innovative polyethylene-glycol fusion technology to improve surgical outcomes in traumatic nerve injuries.
#Biotechnology
Developing a proprietary hand-held soft-mist inhaler for the treatment of asthma and COPD.
#Pharmaceuticals
Provides next-generation molecular testing solutions for oncology and infectious disease.
#Diagnostics
Focused on the development and commercialization of improved treatments for neurodegenerative disorders. Acquired by Allergan for $1B in 2016.
#Pharmaceuticals
Developed products for Dry Eye Disease and Glaucoma. Acquired by Santen for $139M in 2011.
#Pharmaceuticals
Key People
Founder & Managing Partner
Chief Medical Officer & Managing Partner
Managing Partner
Vice President
Vice President
Associate
Analyst
Investor Relations Associate
Executive in Residence